Statistics for First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
Total visits
views | |
---|---|
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer | 5 |
Total visits per month
views | |
---|---|
April 2024 | 5 |
May 2024 | 0 |
June 2024 | 0 |
July 2024 | 0 |
August 2024 | 0 |
September 2024 | 0 |
October 2024 | 0 |
File Visits
views | |
---|---|
Pegram2021FirstHuman-CCBYNCND.pdf | 28 |
Top country views
views | |
---|---|
United States | 4 |
South Korea | 1 |
Top city views
views | |
---|---|
Bloomington | 3 |
Gangnam-gu | 1 |
Muncie | 1 |